Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.36 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.36 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.36 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | ASPH | Q12797 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27672808 | 0.83 | RAB9A (0.46) | HTR2AHTR2CLMNANPC1RAB9A | |
| SCHEMBL3675554 | 0.79 | PTGER1 (0.45) | LMNANPC1RAB9AGAAPTGER1 | |
| SCHEMBL3159391 | 0.76 | ADORA2A (0.50) | HTR2AHTR2CLMNANPC1RAB9A | |
| SCHEMBL5118109 | 0.76 | PTGER1 (0.46) | HTR2AHTR2CNPC1RAB9AGAA | |
| SCHEMBL1431330 | 0.76 | L3MBTL1 (0.37) | HTR2AHTR2CLMNAKMT2AL3MBTL1 | |
| SCHEMBL5423132 | 0.75 | HTR2A (0.36) | HTR2AHTR2CLMNANPC1RAB9A | |
| SCHEMBL15189586 | 0.75 | HTR2A (0.37) | HTR2AHTR2CNPC1RAB9AGAA | |
| SCHEMBL631704 | 0.74 | KDM4E (0.39) | LMNANPC1RAB9APTGER1KMT2A | |
| SCHEMBL2805806 | 0.74 | L3MBTL1 (0.41) | HTR2ALMNAGAAL3MBTL1ALDH1A1 | |
| SCHEMBL19207142 | 0.73 | HCRTR1 (0.48) | TEAD1TEAD4TEAD2TEAD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332518-B2 | Carboxamides as fungicides in agriculture | SYNGENTA CROP PROTECTION, INC. (US) | 2008-02-19 | — | — | US | claimed |
| US-20040138265-A1 | Carboxamides as fungicides in agriculture | SYNGENTA CROP PROTECTION, INC. | 2004-07-15 | — | — | US | claimed |
| CN-1498208-A | Carboxamides as fungicides in agriculture | �ӳɹ� | 2004-05-19 | — | — | CN | claimed |
| EP-1355879-A1 | CARBOXAMIDES AS FUNGICIDES IN AGRICULTURE | Syngenta Participations AG (CH) | 2003-10-29 | — | — | EP | claimed |
| WO-2002059086-A1 | CARBOXAMIDES AS FUNGICIDES IN AGRICULTURE | SYNGENTA PARTICIPATIONS AG (CH) | 2002-08-01 | — | — | WO | claimed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| CN-101052628-A | Isoxazolines derivatives and its weedicide application | ZENECA LTD (GB) | 2007-10-10 | — | — | CN | disclosed |
| EP-1789401-A1 | ISOXAZOLINE DERIVATIVES AND THEIR USE AS HERBICIDES | Syngenta Limited (GB) | 2007-05-30 | — | — | EP | disclosed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006024820-A1 | ISOXAZOLINE DERIVATIVES AND THEIR USE AS HERBICIDES | SYNGENTA LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
| US-20040138265-A1 | Carboxamides as fungicides in agriculture | SYNGENTA CROP PROTECTION, INC. | 2004-07-15 | — | — | US | disclosed |
| CN-1498208-A | Carboxamides as fungicides in agriculture | �ӳɹ� | 2004-05-19 | — | — | CN | disclosed |
| EP-1355879-A1 | CARBOXAMIDES AS FUNGICIDES IN AGRICULTURE | Syngenta Participations AG (CH) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002059086-A1 | CARBOXAMIDES AS FUNGICIDES IN AGRICULTURE | SYNGENTA PARTICIPATIONS AG (CH) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | HTR2A 3531/4885HTR2C 3037/4885LMNA 2896/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | HTR2A 2247/4885HTR2C 1307/4885LMNA 3765/4885 |
| US-20040138265-A1 | Carboxamides as fungicides in agriculture | CBR3, CBR1, CNPY3 | HTR2A 1591/4885HTR2C 320/4885LMNA 2927/4885 |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HTR2A 3621/4885HTR2C 4114/4885LMNA 1656/4885 |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK4, IRAK2, IRAK3 | HTR2A 4314/4885HTR2C 4423/4885LMNA 1420/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HTR2A 3621/4885HTR2C 4114/4885LMNA 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.